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Abstract
Progressive kidney diseases are often associated with scarring of the kidney’s filtration unit, a 
condition called focal segmental glomerulosclerosis (FSGS). This scarring is due to loss of 
podocytes, cells critical for glomerular filtration, and leads to proteinuria and kidney failure. 
Inherited forms of FSGS are caused by Rac1-activating mutations, and Rac1 induces TRPC5 ion 
channel activity and cytoskeletal remodeling in podocytes. Whether TRPC5 activity mediates 
FSGS onset and progression is unknown. We identified a small molecule, AC1903, that 
specifically blocks TRPC5 channel activity in glomeruli of proteinuric rats. Chronic 
administration of AC1903 suppressed severe proteinuria and prevented podocyte loss in a 
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transgenic rat model of FSGS. AC1903 also provided therapeutic benefit in a rat model of 
hypertensive proteinuric kidney disease. These data indicate that TRPC5 activity drives disease 
and that TRPC5 inhibitors may be valuable for the treatment of progressive kidney diseases.
Progressive chronic kidney diseases affect more than 500 million people worldwide and are 
increasing in prevalence (1,2). As a leading cause of kidney failure, focal segmental 
glomerulosclerosis (FSGS) in its most severe form is associated with the nephrotic 
syndrome, which is diagnosed on the basis of proteinuria, the spilling of essential proteins 
into the urine, and histopathologic findings including scarring in large segments of the 
glomerulus, the filtering unit of the kidney (3). This scarring is due to injury and loss of 
terminally differentiated cells of the kidney filter, the podocytes (3,4). Both the proteinuria 
and the histopathologic abnormalities contribute to patient symptoms (such as severe edema 
and shortness of breath) and increase the risk of kidney failure, heart failure, and premature 
death (3). Current therapy for FSGS consists of off-label use of nonspecific medications, 
which do not alter the progression of disease and are associated with toxicities (3).
Inherited and sporadic forms of FSGS are caused by mutations in genes that encode 
regulators of the actin cytoskeleton (5)—specifically, modulators of Rac1. Mutations in 
these genes, including ARHGAP24 (6), ARHGDIA (7), and ARHGEF17 (8), result in 
excess Rac1 signaling in podocytes (6–8). Activation of Rac1 signaling leads to the vesicular 
insertion of transient receptor potential canonical-5 (TRPC5) ion channels into the podocyte 
plasma membrane, making them available for activation by receptors such as the angiotensin 
II type 1 receptor (AT1R) (9,10). This results in transient Ca2+ influx into the podocyte, and 
further Rac1 activation, feeding a circuit that promotes podocyte cytoskeletal remodeling 
(10–12). Because little is known about the pathophysiologic role of the Rac1-TRPC5 
pathway in the onset and progression of FSGS, which is the result of podocyte loss (3), we 
investigated two critical questions: Is this pathway responsible for disease progression in 
FSGS and, if so, can it be blocked for therapeutic benefit?
To study the role of Rac1-TRPC5–mediated podocyte injury in FSGS, we used AT1R 
transgenic (TGNeph-hAT1R/185 or AT1R Tg) rats, which express the human AT1R in a 
podocyte-specific manner (13). Similar to FSGS patients (3), these rats develop all the 
classical features of nephrotic syndrome (13, 14). Because they have podocyte-specific 
expression of the AT1R, these animals do not experience any of the systemic effects of 
excess angiotensin signaling, such as hypertension or vascular disease (13), thus allowing us 
to focus on podocyte-specific pathology. In our studies, AT1R Tg rats developed severe, 
progressive proteinuria over the course of 50 weeks, with onset of disease at 8 to 14 weeks 
and severe escalation in proteinuria beyond 14 weeks (fig. S1A). As a consequence of their 
progressive kidney failure, AT1R Tg rats died at an average age of 400 days, whereas wild-
type (WT) control rats lived beyond 700 days (fig. S1B). In these studies, we focused on 
AT1R Tg rats with established disease (Advanced, ~18 weeks), defined by severe proteinuria 
(>25 mg/day), and compared them to younger rats with early disease (Onset, ~12 weeks, >5 
mg/day proteinuria) (fig. S1A).
We examined TRPC channel activity in isolated rat glomeruli by recording podocyte Ca2+ 
transients in response to angiotensin II (AngII). These experiments suggested that the 
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lanthanum (La3+)- sensitive TRPC6 plays a homeostatic role in WT glomeruli, but TRPC5, 
unmasked by La3+, shows increased activity early on (Onset) and predominates during 
disease progression (Advanced) (fig. S2, A and B). To confirm these results, we used patch-
clamp electrophysiology adapted to the isolated glomeruli preparation. We tested riluzole, a 
direct activator of TRPC5 channel activity (15), and ML204, a tool compound that blocks 
TRPC5 (16). In inside-out recordings of podocytes from AT1R Tg rat glomeruli isolated at 
disease onset, we recorded significant ML204 inhibition of channel activity. In glomeruli 
from rats with established disease (Advanced), riluzole activated a large TRPC5 
conductance, which was blocked by ML204 (Fig. 1, A and B, and fig. S3, A and B). By 
contrast, we recorded minimal riluzole-mediated TRPC5 activation in WT rat glomeruli in 
age-matched controls (Fig. 1, A and B, and fig. S3, A and B). To examine effects on TRPC6 
channels, we used 1-oleoyl-2-acetyl-glycerol (OAG), which directly activates these channels 
(17). We noted no inhibition of ML204 on OAG-induced conductances in recordings from 
age-matched AT1R Tg rats and WT controls (fig. S3C). We therefore excluded the 
possibility that the effect of ML204 can be explained by its targeting of TRPC6 channel 
activity in AT1R Tg rats at any stage of disease progression (fig. S3C). The conclusion from 
Ca2+ imaging and electrophysiology in rat glomeruli is that TRPC5-mediated Ca2+ influx in 
podocytes correlates with FSGS disease progression (Fig. 1C).
We next tested the efficacy of ML204 in vivo. Intraperitoneal administration of ML204 
twice daily for 7 days to animals at disease onset induced remission of proteinuria: Urine 
protein concentrations in treated rats were comparable to those in WT controls (fig. S4, A 
and B). Furthermore, administration of ML204 (25 mg/kg) twice daily over the course of 14 
days in rats with severe disease (Advanced) suppressed progression of proteinuric disease at 
7 days and 14 days (Fig. 1D) without evidence of toxicity (fig. S4, C to G). Control AT1R 
Tg animals continued to have escalating proteinuria (Fig. 1D). Morphometric analysis 
(18,19) (see methods) showed that ML204 prevented podocyte loss in AT1R Tg rats with 
advanced disease, maintaining the numbers of podocytes at near-baseline WT levels, in 
contrast to significant podocyte loss in control phosphate-buffered saline (PBS)–treated 
AT1R Tg rats (Fig. 1E). AT1R Tg rats with advanced disease also had numerous podocyte 
pseudocysts (fig. S4H), similar to previously described pseudocysts leading to podocyte loss 
through detachment from the basement membrane in various models of FSGS (20). 
Treatment with ML204 prevented pseudocyst formation, suggesting that podocytes were 
rescued from detachment and loss (fig. S4, H and I). Thus, podocyte numbers are preserved 
by treatment with ML204.
Because ML204 blocks TRPC5 and TRPC4 channels, and weakly blocks TRPC6 channels 
(16), we set out to develop a more specific TRPC5 inhibitor. We sought a compound with 
podocyte-protective properties and no unwanted on-target effects on TRPC4 channels 
[which, although not expressed in podocytes (10), are expressed in endothelium (21)] or 
TRPC6 channels. Based on the structures of published blockers (16,22), we synthesized and 
tested a series of 50 molecules for activity against TRPC5, TRPC4, and TRPC6 and 
identified compound AC1903 (Fig. 2A) as a promising candidate. Patch-clamp 
electrophysiology experiments in human embryonic kidney 293 (HEK-293) cells expressing 
TRPC5, TRPC4, or TRPC6 revealed that AC1903 is TRPC5-selective: In dose-response 
experiments, it blocked riluzole-activated TRPC5 whole-cell current, but failed to block 
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carbachol (CCh)–induced TRPC4 and OAG-induced TRPC6 currents, even at high 
micromolar concentrations (Fig. 2B and fig. S5, A to C). We also compared the dose 
responses of AC1903 and ML204 and found that the two inhibitors were nearly equipotent, 
with half-maximal inhibitory concentration of ML204 (IC50 ML204) = 13.6 μM versus 
IC50 AC1903 = 14.7 μM (Fig. 2C). In standard kinase profiling assays, AC1903 did not have 
offtarget effects (table S1). Thus, AC1903 selectively blocks TRPC5 ion channels.
Rac1 activation leads to increased production of reactive oxygen species (ROS) (23,24). To 
establish a mechanistic understanding for the effects of AC1903 on the Rac1-TRPC5 
pathway in podocytes, we measured ROS levels in vitro in podocytes treated with AngII 
(Fig. 2D). AngII treatment induced a significant increase in ROS, which was blocked by 
AC1903 and the ROS scavenger N-acetylcysteine (NAC) (Fig. 2D). Next, we engineered 
podocytes to overexpress a well-characterized, constitutively active mutant of the human 
AT1R, which is unable to inactivate and undergo endocytosis (caAT1R) (25). Increased ROS 
production was detected in the presence of caAT1R (Fig. 2E). AC1903, ML204, and the 
Rac1 inhibitor (NSC23677) blocked caAT1R-induced ROS generation (Fig. 2E). We also 
noted increased podocyte cell death within 36 hours of caAT1R expression (Fig. 2F). By 
contrast, podocytes treated with AC1903, ML204, or the Rac1 inhibitor were protected from 
cell death (Fig. 2F). These data suggest that excess ROS production contributes to the 
molecular events linking Rac1-TRPC5 signaling to podocyte loss.
After characterizing the pharmacokinetic properties of AC1903 (fig. S6), we investigated 
whether AC1903 could suppress proteinuria in AT1R Tg rats with established disease. 
Twice-daily intraperitoneal injections of AC1903 (50 mg/kg) for 7 days suppressed severe 
proteinuria in AT1R Tg rats (Advanced) (Fig. 3A), without evidence of toxicity (fig. S7, A 
to C). Inside-out electrophysiology measurements in isolated glomeruli from AT1R Tg rats 
confirmed that AC1903 blocks TRPC5 channel activity during proteinuric disease 
progression (Fig. 3, B and C). Morphometric analysis demonstrated that treatment with 
AC1903 led to a significant reduction in pseudocyst formation and in podocyte loss in AT1R 
Tg rats with advanced disease (Fig. 3, D to F). Thus, AC1903 inhibits the progression of 
proteinuric kidney disease by preserving podocytes.
To characterize the transcriptional responses to AC1903-mediated inhibition of Rac1-
TRPC5 signaling and enhanced podocyte survival in vivo, we compared gene expression 
profiles [RNA sequencing (RNA-seq)] in isolated glomeruli from WT rats, AC1903-treated 
AT1R Tg rats in the advanced cohort, and vehicle-treated, age-matched AT1R Tg controls 
(fig. S8A). We identified 541 differentially expressed genes in AT1R Tg rats compared to 
WT controls (table S2 and fig. S8B). In support of the hypothesis that Rac1-mediated ROS 
generation and TRPC5 Ca2+ (cation) –mediated signaling lead to disease progression, Gene 
Ontology (GO) term enrichment analysis revealed ROS-related and cation channel and 
transporter activity gene signatures (fig. S8C). In line with this, ROS-related genes 
previously implicated in podocyte injury such as Nox4 (26,27) were found to be up-
regulated. After treatment with AC1903,42 genes were differentially expressed in AC1903-
treated versus vehicle-treated AT1R Tg rats (table S2 and fig. S8B). This smaller number of 
genes suggests that AC1903 targets a specific signaling network to confer its therapeutic 
benefit. GO term enrichment analysis revealed cell adhesion and integrin signaling gene sets, 
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in support of the notion that AC1903 fortifies the cytoskeleton, prevents pseudocysts, and 
promotes cell adhesion to prevent podocyte loss (table S2 and fig. S8D).
We also investigated the efficacy of AC1903 in Dahl salt-sensitive (Dahl S) rats, a model of 
hypertension-induced FSGS (28,29) that recapitulates many of the systemic conditions 
leading to progressive proteinuric kidney disease in patients. On a low-salt diet, Dahl S rats 
exhibit progressive, age-related kidney injury with moderate hypertension. On a high-salt 
diet, Dahl S rats demonstrate progressive nephrotic range proteinuria and decline in kidney 
function with AngII-mediated hypertension (30,31). We administered AC1903 or a vehicle 
control to hypertensive Dahl S rats with salt loading (2% NaCl). First, we initiated injection 
of AC1903 (50 mg/kg twice daily i.p.) into 6-week-old Dahl S rats at the start of 2% NaCl 
diet (Onset, Fig. 4A). As expected, control rats developed severe and escalating proteinuria 
within a week of salt administration. By contrast, the rate of progressive proteinuria in 
AC1903-treated animals was significantly reduced (Fig. 4A). Next, we asked whether 
AC1903 could suppress progressive proteinuria in rats with more advanced disease. Here, 6-
week-old Dahl S rats received 2% NaCl for 1 week, leading to severe, progressive 
proteinuric disease (Advanced, Fig. 4B). AC1903 treatment was initiated on day 7, and 
animals were treated for 1 week until day 14 (2-week salt loading). Whereas progressive 
proteinuria continued to escalate in control rats, AC1903-treated rats had significant 
suppression of proteinuria (Fig. 4B) with preserved podocyte numbers (Fig. 4C). 
Morphometric analysis showed that the numbers of podocytes in AC1903-treated Dahl S rats 
was higher compared to vehicle-treated controls, and similar to the numbers of podocytes in 
WT and AC1903-treated AT1R Tg rats (~120 podocytes per glomerulus; Figs. 1E, 3F, and 
4C). AC1903 had no effect on body weight, blood urea nitrogen, or creatinine in Dahl S rats 
in these experiments (fig. S9, A to C). Notably, treatment with AC1903 did not affect the 
mean arterial pressure (MAP), suggesting that the therapeutic benefit is not related to 
changes in blood pressure but more likely is due to a protective effect on podocytes (Fig. 
4D).
Our animal data demonstrate that a specific TRPC5 small-molecule inhibitor administered at 
the time of severe, established proteinuria, but before creatinine is elevated, can rescue 
podocytes and attenuate the progression of morphologic and molecular changes that 
characterize FSGS (fig. S10). These findings provide a mechanistic rationale for 
therapeutically targeting TRPC5 channels, in contrast to earlier work, which had 
extrapolated from TRPC6 gain-of-function mutations to suggest a role for TRPC6 inhibition 
in acquired FSGS (32). Our real-time measurements of single-channel activity in isolated 
glomeruli show that increased TRPC5 activity is associated with proteinuric disease 
progression, whereas TRPC6 activity appears to be homeostatic. This is supported by the 
observation that (in addition to gain-of-function mutations) loss-of-function mutations in 
TRPC6 also lead to FSGS (33). Our early data with the hypertensive Dahl S rat model 
support a broader applicability of TRPC5 inhibition as a therapeutic strategy.
In the context of precision medicine, genomic sequencing efforts may help identify a patient 
population with mutations in genes that result in Rac1 activation for initial clinical studies. 
Although careful toxicology studies will be needed before taking TRPC5 inhibitors into the 
clinic, several lines of evidence are reassuring: Rats treated with TRPC5 inhibitor for up to 
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14 days show no detectable toxicity, and mice genetically lacking TRPC5 from birth show 
no gross abnormalities, except for an attenuated fear response due to a developmental defect 
in the amygdala (34). The promising preclinical results with TRPC5 inhibitors suggest that 
these drugs may form the basis of much-needed, mechanistically based therapies for 
progressive chronic kidney diseases.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. Escalating TRPC5 ion channel activity correlates with disease progression, and TRPC5 
inhibition rescues podocytes in AT1R Tg rats
(A) ML204 (1 μM) blocks TRPC5 single-channel activity induced by Riluzole (Rilu, 3 μM) 
in inside-out recordings from rat glomeruli isolated during early disease (Onset), as 
compared to barely detectable current in age-matched WT glomeruli (Onset). ML204 blocks 
a significantly greater Rilu-activated conductance in glomeruli from rats with established 
disease (Advanced), compared to minimal TRPC5 activity in age-matched WT glomeruli 
(Advanced). C, close state; O1, open channel level 1; O2, open channel level 2. Vm = −60 
mV. (B) Quantification of open channel probability (NPo) for the conductances recorded in 
(A). WT Rilu n = 4 and 5, WT Rilu + ML204 n = 4 and 5, AT1R Tg Rilu n = 4 and 5, AT1R 
Tg Rilu + ML204 n = 4 and 5 for Onset and Advanced groups, respectively. Mean ± SEM, 
*P < 0.05, **P < 0.01. (C) TRPC6 channel activity contributes to podocyte Ca2+ 
homeostasis. TRPC5 activity is coincident with onset of proteinuria and correlates with 
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FSGS disease progression. (D) Progressive proteinuria suppressed by twice-per-day i.p. 
administration of ML204 in the Advanced cohort of AT1R Tg rats treated for 14 days. AT1R 
Tg PBS n = 23, AT1R Tg ML204 n= 23. Mean ± SEM, *P < 0.05, **P < 0.01. (E) Rescue 
of podocyte numbers in vivo in ML204-treated AT1R Tg rats with established disease 
(Advanced). WT PBS n = 7, AT1R Tg PBS n = 8, AT1R Tg ML204 n = 8. Mean ± SEM, 
**P < 0.01.
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Fig. 2. AC1903, a specificTRPC5 small-molecule inhibitor, protects podocytes from ROS-
mediated injury
(A) Chemical structure of AC1903. (B) Selectivity of AC1903 (1 to 100 μM) for TRPC5 
over TRPC4 and TRPC6 in dose-response patch-clamp experiments in the whole-cell 
configuration. n > 3 for each dose. Mean ± SEM. (C) Equipotency between AC1903 and 
ML204 in dose-response patch-clamp experiments in the whole-cell configuration in 
response to Rilu (3 μM). ML204 n >3, AC1903 n > 3 for each dose Mean ± SEM. (D) ROS 
generation blocked by AC1903 (30 μM) in vitro in WT podocytes treated with AngII (10 
μM). DMSO, dimethyl sulfoxide; Veh, vehicle. DMSO + Veh n = 23, Ang II + Veh n = 23, 
Ang II + AC1903 n = 24, Ang II + NAC n = 24, each from three independent replicates. 
Mean ± SEM, ***P < 0.001. (E) ROS generation blocked by AC1903 (30 μM), ML204 (30 
μM), and NSC23677 (50 μM) in vitro in caAT1R-expressing podocytes. Veh n = 40 and 60; 
ML204 n = 40 and 60; AC1903 n = 40 and 60; NSC23677 n = 40 and 60, for control and 
caAT1R-expressing podocytes, respectively, each from four independent replicates. Mean ± 
SEM, **P < 0.01. (F) Podocyte cell death rescued by AC1903 (30 μM), ML204 (30 μM), 
and NSC23677 (50 μM). Control n = 24, Veh n = 24, ML204 n = 24, AC1903 n = 24, 
NSC23677 n = 12, each from four independent replicates. Mean ± SEM, *P < 0.05.
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Fig. 3. AC1903 suppresses proteinuric kidney disease progression and rescues podocytes in AT1R 
Tg rats with advanced disease
(A) AC1903 (50 mg/kg) ameliorates proteinuria in AT1R Tg rats with established, advanced 
disease. Veh n = 13, AC1903 n = 14. Mean ± SEM, ***P < 0.001. (B) AC1903 inhibition of 
TRPC5 channel activity in insideout recordings from advanced-disease AT1R rat glomeruli. 
(C) Quantification of open channel probability (NPo) for the conductances recorded in (B). 
Each n = 6. Mean ± SEM, *P < 0.05. (D) Toluidine blue semithin sections of rat kidneys. 
Red asterisks indicate pseudocysts. Bar, 50 μM. (E) Reduction of pseudocyst volume in 
AT1R Tg AC1903 rats compared to AT1R Tg vehicle rats. WT Veh n = 7, AT1R Tg Veh n = 
7, AT1R Tg AC1903 n = 7. Mean ± SEM, *P < 0.05, **P < 0.01. (F) Rescue of podocyte 
numbers in vivo in AC1903-treated AT1R Tg rats with established disease (Advanced). WT 
Veh n = 7, AT1R Tg Veh n = 7, AT1R Tg AC1903 n = 7, Advanced. Mean ± SEM, *P < 
0.05.
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Fig. 4. AC1903 suppresses proteinuric kidney disease progression and rescues podocytes in 
hypertensive Dahl S rats
(A) AC1903 (50 mg/kg) ameliorates proteinuria in Dahl S rats when administered at the 
same time as high salt intake (Onset). Veh n = 8, AC1903 n = 8. Mean ± SEM, ***P < 
0.001. (B) AC1903 (50 mg/kg) suppresses proteinuria in Dahl S rats with established, 
advanced disease (Advanced). Veh n = 9, AC1903 n = 14. Mean ± SEM, ***P < 0.001. (C) 
Rescue of podocyte numbers in vivo in AC1903-treated Dahl S rats with established disease 
(Advanced). Veh n = 9, AC1903 n = 14. Mean ± SEM, *P < 0.05. (D) Administration of 
AC1903 has no detectable effect on mean arterial pressure (MAP) of Dahl S rats. Veh n = 9, 
AC1903 n = 14. Mean ± SEM.
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